Following his presentation at ACR 2020 we spoke with Ronald van Vollenhoven (Amsterdam University Medical Centers, Amsterdam, the Netherlands) regarding upadacitinib monotherapy in methotrexate-naïve patients with rheumatoid arthritis. (Clinical Trial Identifier: NCT02706873). The abstract ‘Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks’ (ABSTRACT NUMBER: 0207) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What is the rationale for the use of JAK inhibitors in the treatment of rheumatoid arthritis (RA)? (0:25)
- How does upadacitinib fit into the current treatment paradigm for RA? (1:52)
- Could you give us an overview of the SELECT-EARLY study and its findings? (3:19)
- What have the latest data taught us about the long term efficacy and safety of upadacitinib? (4:27)
- What are the remaining gaps in our knowledge regarding the optimal use of upadacitinib in RA, and what further studies are planned? (5:35)
Disclosures: Research Support (institutional grants): BMS, GSK, Lilly, UCB. Support for Educational programs (institutional grants): Pfizer, Roche. Consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB. Speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer, UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual)
Share this Video
Related Videos In Rheumatoid Arthritis
Andrea Rubbert-Roth, EULAR 2021: The Phase 3 SELECT-CHOICE Study
It was a pleasure to meet with Prof. Andrea Rubbert-Roth (Kantonsspital St Gallen, St Gallen, Switzerland) to discuss the comparative efficacy of upadacitinib and abatacept in patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. The abstract ‘Clinical responses to upadacitinib or abatacept in patients with rheumatoid arthritis by type of prior biologic disease-modifying […]
Roy Fleischmann, EULAR 2021: The Open-label Extension of the SELECT-COMPARE Study
TouchIMMUNOLOGY were delighted to talk with Professor Roy Fleischmann (The University of Texas Southwestern Medical Center and The Metroplex Clinical Research Center, Dallas, TX, US) around the 3 year results from the open-label extension study of upadacitinib or adalimumab in patients with rheumatoid arthritis. ‘Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with […]
Peter Taylor, EULAR 2021: Coadministration of Filgotinib and Statins in Rheumatoid Arthritis
We were delighted to speak with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) around the safety of statin and filgotinib coadministration in patients with rheumatoid arthritis across the DARWIN and FINCH clinical trials. The abstract ‘CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS‘ (POS0660), was presented at the European […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!